Title: Crystallization, spectral, crystallographical, and thermoanalytical studies of succinobucol polymorphism.
Journal: Journal of pharmaceutical sciences 20120501
Title: Succinobucol induces apoptosis in vascular smooth muscle cells.
Journal: Free radical biology & medicine 20120301
Title: Succinobucol's new coat--conjugation with steroids to alter its drug effect and bioavailability.
Journal: Molecules (Basel, Switzerland) 20111110
Title: Assessment of coronary atherosclerosis by IVUS and IVUS-based imaging modalities: progression and regression studies, tissue composition and beyond.
Journal: The international journal of cardiovascular imaging 20110201
Title: [Novel therapy for atherosclerosis and inflammatory vascular disease].
Journal: Nihon rinsho. Japanese journal of clinical medicine 20110101
Title: Study design and rationale of 'Synergistic effect of combination therapy with cilostazol and ProbUcol on plaque stabilization and lesion REgression (SECURE)' study: a double-blind randomised controlled multicenter clinical trial.
Journal: Trials 20110101
Title: Role for inducible cAMP early repressor in promoting pancreatic beta cell dysfunction evoked by oxidative stress in human and rat islets.
Journal: Diabetologia 20110101
Title: Probucol and succinobucol in atrial fibrillation: pros and cons.
Journal: International journal of cardiology 20101008
Title: Emerging drugs for hyperlipidemia.
Journal: Expert opinion on emerging drugs 20100901
Title: AGI-1067, a novel antioxidant and anti-inflammatory agent, enhances insulin release and protects mouse islets.
Journal: Molecular and cellular endocrinology 20100729
Title: Impact of medical therapy on atheroma volume measured by different cardiovascular imaging modalities.
Journal: Cardiology research and practice 20100101
Title: Analyses of copy number variation of GK rat reveal new putative type 2 diabetes susceptibility loci.
Journal: PloS one 20100101
Title: Heme oxygenase-1 increases endothelial progenitor cells.
Journal: Arteriosclerosis, thrombosis, and vascular biology 20091001
Title: Malformed mdx myofibers have normal cytoskeletal architecture yet altered EC coupling and stress-induced Ca2+ signaling.
Journal: American journal of physiology. Cell physiology 20090901
Title: Molecular mechanisms underlying the antiatherosclerotic and antidiabetic effects of probucol, succinobucol, and other probucol analogues.
Journal: Current opinion in lipidology 20090601
Title: Selective thromboxane inhibition after vascular protectant AGI-1067: results of assessment of lipoprotein profiles (ALPS) biomarkers in vitro and in vivo substudy.
Journal: Journal of thrombosis and thrombolysis 20090501
Title: Succinobucol: review of the metabolic, antiplatelet and cardiovascular effects.
Journal: Expert opinion on investigational drugs 20090401
Title: Diabetes treatment.
Journal: Diabetes care 20090301
Title: Current and emerging paradigms in the therapeutic management of atherosclerosis.
Journal: Expert opinion on therapeutic targets 20081201
Title: Gateways to clinical trials.
Journal: Methods and findings in experimental and clinical pharmacology 20080901
Title: Novel cardiac therapies and innocent by standers.
Journal: Lancet (London, England) 20080524
Title: Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial.
Journal: Lancet (London, England) 20080524
Title: Effects of the antioxidant succinobucol (AGI-1067) on human atherosclerosis in a randomized clinical trial.
Journal: Atherosclerosis 20080301
Title: Gateways to clinical trials. July-August 2008.
Journal: Methods and findings in experimental and clinical pharmacology 20080101
Title: Clinical trials update from the European Society of Cardiology Congress in Vienna, 2007: PROSPECT, EVEREST, ARISE, ALOFT, FINESSE, Prague-8, CARESS in MI and ACUITY.
Journal: Cardiovascular drugs and therapy 20071201
Title: Pharmacologic approaches to restenosis prevention.
Journal: The American journal of cardiology 20070903
Title: A novel class of antioxidants inhibit LPS induction of tissue factor by selective inhibition of the activation of ASK1 and MAP kinases.
Journal: Arteriosclerosis, thrombosis, and vascular biology 20070801
Title: Assessment of lipoprotein profiles study (ALPS) and antioxidant activity in healthy subjects treated with AGI-1067.
Journal: Journal of clinical lipidology 20070801
Title: AGI-1067, a novel vascular protectant, anti-inflammatory drug and mild antiplatelet agent for treatment of atherosclerosis.
Journal: Expert review of cardiovascular therapy 20070701
Title: Follicular development and expression of the messenger ribonucleic acid for the inhibin/activin subunits in two genetic lines of turkey hens that differ in total egg production.
Journal: Poultry science 20070501
Title: Vascular cell adhesion molecule-1: a viable therapeutic target for atherosclerosis?
Journal: International journal of clinical practice 20070401
Title: [Research and developmental strategy of anti-dyslipidemic agents].
Journal: Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20070401
Title: American Heart Association - Scientific Sessions 2006. Cell therapies for ischemic tissues and treatments for lipid metabolism disorders.
Journal: IDrugs : the investigational drugs journal 20070101
Title: Gateways to clinical trials.
Journal: Methods and findings in experimental and clinical pharmacology 20070101
Title: The in vitro effects of a novel vascular protectant, AGI-1067, on platelet aggregation and major receptor expression in subjects with multiple risk factors for vascular disease.
Journal: Journal of cardiovascular pharmacology and therapeutics 20060901
Title: Are small biotechs still underselling themselves?
Journal: Nature biotechnology 20060501
Title: Antioxidants: the good, the bad and the ugly.
Journal: The Canadian journal of cardiology 20060201
Title: AGI-1067: a novel vascular protectant for prevention of restenosis.
Journal: The Annals of pharmacotherapy 20060101
Title: Antioxidants and atherosclerosis: emerging drug therapies.
Journal: Current atherosclerosis reports 20050201
Title: Inhibition of lipoprotein lipid oxidation.
Journal: Handbook of experimental pharmacology 20050101
Title: Discovery of novel phenolic antioxidants as inhibitors of vascular cell adhesion molecule-1 expression for use in chronic inflammatory diseases.
Journal: Journal of medicinal chemistry 20041202
Title: Selective inhibition of endothelial and monocyte redox-sensitive genes by AGI-1067: a novel antioxidant and anti-inflammatory agent.
Journal: The Journal of pharmacology and experimental therapeutics 20040301
Title: Pharmacologic prevention of both restenosis and atherosclerosis progression: AGI-1067, probucol, statins, folic acid and other therapies.
Journal: Current opinion in lipidology 20031201
Title: Experimental and clinical studies show that the probucol derivative AGI-1067 prevents vascular growth.
Journal: Expert opinion on investigational drugs 20031101
Title: Vascular protectants for the treatment of atherosclerosis.
Journal: Expert review of cardiovascular therapy 20030901
Title: Signal jammer. An academic experiment leads to a new class of drug for attacking heart disease.
Journal: Scientific American 20030701
Title: AGI-1067: a multifunctional phenolic antioxidant, lipid modulator, anti-inflammatory and antiatherosclerotic agent.
Journal: The Journal of pharmacology and experimental therapeutics 20030601
Title: Chemistry and pharmacology of vascular protectants: a novel approach to the treatment of atherosclerosis and coronary artery disease.
Journal: The American journal of cardiology 20030206
Title: Clinical results with AGI-1067: a novel antioxidant vascular protectant.
Journal: The American journal of cardiology 20030206
Title: Effects of AGI-1067 and probucol after percutaneous coronary interventions.
Journal: Circulation 20030204
Title: Drug reverses coronary atherosclerosis.
Journal: Drug discovery today 20020101
Title: Houston SA, et al. An investigation of the antiplatelet effects of succinobucol (AGI-1067). Platelets. 2017 May;28(3):295-300.
Title: Colle D, et al. Succinobucol, a Lipid-Lowering Drug, Protects Against 3-Nitropropionic Acid-Induced Mitochondrial Dysfunction and Oxidative Stress in SH-SY5Y Cells via Upregulation of Glutathione Levels and Glutamate Cysteine Ligase Activity. Mol Neurobiol. 2016 Mar;53(2):1280-95.
Title: Dan Z, et al. A pH-Responsive Host-guest Nanosystem Loading Succinobucol Suppresses Lung Metastasis of Breast Cancer. Theranostics. 2016 Jan 25;6(3):435-45.
